Tony Michael Argenbright

Array ( [id] => 17687780 [patent_doc_number] => 20220195072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => TARGETED ANTICOAGULANT [patent_app_type] => utility [patent_app_number] => 17/548204 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17548204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578776 [patent_doc_number] => 20220135631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => SECRETORY PROTEIN [patent_app_type] => utility [patent_app_number] => 17/521286 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17521286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17576989 [patent_doc_number] => 20220133844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/512298 [patent_app_country] => US [patent_app_date] => 2021-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17512298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482153 [patent_doc_number] => 20220089657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => MODIFIED PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/491067 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17491067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748230 [patent_doc_number] => 20220226433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Method to Identify Responders to Osteoarthritis Therapeutics [patent_app_type] => utility [patent_app_number] => 17/486551 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503491 [patent_doc_number] => 20220096593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHOD AND COMPOSITIONS COMPRISING A CT20 PEPTIDE [patent_app_type] => utility [patent_app_number] => 17/486432 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334639 [patent_doc_number] => 20220000970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => USE OF CHELATING AGENT AND PEPTIDE ANTIMICROBIAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/485345 [patent_app_country] => US [patent_app_date] => 2021-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17485345 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414055 [patent_doc_number] => 20220048959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => ANTIMICROBIAL PROTEIN [patent_app_type] => utility [patent_app_number] => 17/485346 [patent_app_country] => US [patent_app_date] => 2021-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17485346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343634 [patent_doc_number] => 20220009965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => PEPTIDE INHIBITORS OF TIGHT JUNCTION PERMEABILITY [patent_app_type] => utility [patent_app_number] => 17/483934 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640652 [patent_doc_number] => 20220168390 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTOR [patent_app_type] => utility [patent_app_number] => 17/481490 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17481490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370063 [patent_doc_number] => 20220025115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => Methods for Measuring Consumption of Amino Acid N-Carboxyanhydrides during Manufacture of Glatiramer Acetate [patent_app_type] => utility [patent_app_number] => 17/403278 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399588 [patent_doc_number] => 20220041678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => SOLUBLE NPY2 RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 17/394522 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 452 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18801328 [patent_doc_number] => 11834480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Protein inhibitors with reduced immunogenicity and resistance to degradation, and methods for their preparation and use [patent_app_type] => utility [patent_app_number] => 17/391805 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 18288 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17391805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368340 [patent_doc_number] => 20220023392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART [patent_app_type] => utility [patent_app_number] => 17/367339 [patent_app_country] => US [patent_app_date] => 2021-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398177 [patent_doc_number] => 20220040267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/367340 [patent_app_country] => US [patent_app_date] => 2021-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414063 [patent_doc_number] => 20220048967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => GIP/GLP1 CO-AGONIST COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/366998 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30277 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168843 [patent_doc_number] => 20210322513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => METHOD FOR DETECTING CANCER CELLS, REAGENT FOR INTRODUCING SUBSTANCE INTO CANCER CELLS, AND COMPOSITION FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/364162 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17364162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18064473 [patent_doc_number] => 20220395560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) [patent_app_type] => utility [patent_app_number] => 17/362191 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342216 [patent_doc_number] => 20220008547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => Carrier Peptide Fragment and use Thereof [patent_app_type] => utility [patent_app_number] => 17/361498 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17361498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312901 [patent_doc_number] => 20210401949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute [patent_app_type] => utility [patent_app_number] => 17/357374 [patent_app_country] => US [patent_app_date] => 2021-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357374 [rel_patent_id] =>[rel_patent_doc_number] =>)